HDAC9 and lung carcinoma: Zheng et al. found that the HDAC inhibitor romidepsin enhances T cell chemokine expression and promoted T cell infiltration in mouse models of lung cancer, resulting in a strongly augmented response to PD-1 inhibitor (5).